abrocitinib (Cibinqo)
Jump to navigation
Jump to search
Indications
- atopic dermatitis
- persons >= 12 years with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products
Contraindications
- use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressant not advised
- use in combination with antiplatelet therapies, except for low-dose aspirin during the first 3 months of treatment
Dosage
- 100 mg orally once daily
- 200 mg orally once daily if not responding to 100 mg once daily
- moderate renal impairment or CYP2C19 poor metabolizer:
- 50 mg once daily or 100 mg once daily if not responding to 50 mg once daily
Adverse effects
* dose-dependent (% for 200 mg dose)
- drug adverse effects of tyrosine kinase inhibitor(s)
- drug adverse effects of janus kinase inhibitors
Mechanism of action
- Janus kinase 1 (JAK1) inhibitor
- reduces interleukin-4 & interleukin-13 signaling
More general terms
References
- ↑ Bieber T, Simpson EL, Silverberg JT et al Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med 2021; 384:1101-1112. March 25 PMID: https://pubmed.ncbi.nlm.nih.gov/33761207 https://www.nejm.org/doi/full/10.1056/NEJMoa2019380
- ↑ Highlights of Prescribing Information CIBINQO <TM> (abrocitinib) tablets, for oral use https://labeling.pfizer.com/ShowLabeling.aspx?id=16652